NASDAQ · CYTH
Cyclo Therapeutics, Inc.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
Loading market information…
NASDAQ · BIOL · USD
Stock price, dividends, earnings
Quote as of Oct 2, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BIOLASE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
BIOLASE, Inc.’s forward annual dividend is $431.24 per share, paid quarterly. The forward yield is 2,156,182.8% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BIOLASE, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BIOLASE, Inc., along with its various divisions, operates as a global enterprise specializing in the creation, production, distribution, and sale of advanced laser systems. These technologies are specifically designed for dental professionals and their patients across the United States and internationally. The sophisticated laser instruments developed by BIOLASE empower a diverse array of dental specialists—including general dentists, periodontists, endodontists, and oral surgeons—to execute a broad spectrum of minimally invasive procedures. These applications range from cosmetic enhancements and restorative treatments to intricate surgical interventions. Among its core product offerings, the company provides Waterlase all-tissue dental laser systems, which are highly effective for precisely cutting both soft and hard tissues. It also supplies diode soft-tissue laser systems, utilized for procedures involving soft tissue, pain management, teeth whitening, and various other aesthetic treatments. Furthermore, the Epic Hygiene laser assists in addressing non-surgical periodontitis and enhancing overall clinical efficiency. Beyond its primary laser devices, BIOLASE also manufactures and distributes essential consumable items and accessories. This comprehensive range includes flexible fibers, specialized hand pieces, and professional teeth whitening gel kits. The company markets its products through a dedicated in-house sales team and an extensive network of distributors. Established in 1984, the organization was initially known as BIOLASE Technology, Inc., before officially changing its name to BIOLASE, Inc. in 2012. Its corporate headquarters are situated in Foothill Ranch, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2022 | Mar 28, 2023 | -$128.00-20,100.0% vs estimate | $14.05M-0.14% vs estimate |
|---|
| Q3 2022 | Nov 10, 2022 | -$110.00-12,995.24% vs estimate | $12.01M+12.73% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$1.99+$0.02 (+1.02%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.0% below the high.
$0.73-$0.03 (-3.84%)
Anew Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.79% below the high.
$0.03$0.00 (0.0%)
Accelerate Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.37% below the high.
$0.66-$0.21 (-24.02%)
Acorda Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.27% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
$0.47-$0.01 (-1.58%)
GBS Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.63% below the high.
$0.11$0.00 (0.0%)
Longevity Health Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.41% below the high.
